-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Jefferies Financial Group Analysts Increase Earnings Estimates for Calliditas Therapeutics AB (Publ) (NASDAQ:CALT)
Jefferies Financial Group Analysts Increase Earnings Estimates for Calliditas Therapeutics AB (Publ) (NASDAQ:CALT)
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) – Research analysts at Jefferies Financial Group boosted their FY2023 earnings estimates for Calliditas Therapeutics AB (publ) in a research report issued to clients and investors on Friday, August 19th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will earn $4.11 per share for the year, up from their previous estimate of $3.91. The consensus estimate for Calliditas Therapeutics AB (publ)'s current full-year earnings is ($2.81) per share. Jefferies Financial Group also issued estimates for Calliditas Therapeutics AB (publ)'s FY2024 earnings at $6.74 EPS, FY2025 earnings at $8.69 EPS and FY2026 earnings at $11.10 EPS.
Get Calliditas Therapeutics AB (publ) alerts:Several other research firms have also commented on CALT. Pareto Securities started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They set a "buy" rating for the company. Kepler Capital Markets started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They set a "buy" rating for the company. Finally, TheStreet upgraded shares of Calliditas Therapeutics AB (publ) from a "d+" rating to a "c-" rating in a research report on Thursday, August 4th.
Calliditas Therapeutics AB (publ) Stock Down 10.4 %
Calliditas Therapeutics AB (publ) stock opened at $16.13 on Monday. The company has a 50-day simple moving average of $18.77 and a 200-day simple moving average of $18.27. The firm has a market capitalization of $429.46 million, a P/E ratio of -6.48 and a beta of 1.60. The company has a debt-to-equity ratio of 0.25, a quick ratio of 5.36 and a current ratio of 5.37. Calliditas Therapeutics AB has a one year low of $12.55 and a one year high of $32.24.Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)
A hedge fund recently raised its stake in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC raised its holdings in Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after acquiring an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 25.10% of the company's stock.
About Calliditas Therapeutics AB (publ)
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Read More
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- Near-Term Headwinds Present An Opportunity In Ross Stores
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) – Research analysts at Jefferies Financial Group boosted their FY2023 earnings estimates for Calliditas Therapeutics AB (publ) in a research report issued to clients and investors on Friday, August 19th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will earn $4.11 per share for the year, up from their previous estimate of $3.91. The consensus estimate for Calliditas Therapeutics AB (publ)'s current full-year earnings is ($2.81) per share. Jefferies Financial Group also issued estimates for Calliditas Therapeutics AB (publ)'s FY2024 earnings at $6.74 EPS, FY2025 earnings at $8.69 EPS and FY2026 earnings at $11.10 EPS.
卡里迪塔斯治疗公司(Publ)(纳斯达克代码：CALT-GET Rating)-杰富瑞金融集团的研究分析师在8月19日(星期五)发布给客户和投资者的一份研究报告中上调了他们对卡里迪塔斯治疗公司(Publ)2023财年的收益预期。杰富瑞金融集团(Jefferies Financial Group)分析师雷克罗夫特(M.Raycroft)现在预计，该公司今年的每股收益为4.11美元，高于此前预测的3.91美元。对Calliditas Treateutics AB(Publ)目前全年收益的普遍预期为每股2.81美元。Jefferies Financial Group还发布了对Calliditas Treateutics AB(Publ)2024财年每股收益6.74美元、2025财年每股收益8.69美元和2026财年每股收益11.10美元的预期。
Several other research firms have also commented on CALT. Pareto Securities started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 2nd. They set a "buy" rating for the company. Kepler Capital Markets started coverage on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, June 16th. They set a "buy" rating for the company. Finally, TheStreet upgraded shares of Calliditas Therapeutics AB (publ) from a "d+" rating to a "c-" rating in a research report on Thursday, August 4th.
其他几家研究公司也对CALT发表了评论。帕累托证券于6月2日星期四在一份研究报告中开始报道Calliditas Treateutics AB(Publ)的股票。他们为该公司设定了“买入”评级。开普勒资本市场于6月16日星期四在一份研究报告中开始报道Calliditas Treateutics AB(Publ)的股票。他们为该公司设定了“买入”评级。最后，在8月4日星期四的一份研究报告中，华尔街将Calliditas治疗公司(Publ)的股票评级从“d+”上调至“c-”。
Calliditas Therapeutics AB (publ) Stock Down 10.4 %
Calliditas Treateutics AB(Publ)股价下跌10.4%
Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)
机构投资者买入Calliditas Treateutics AB(Publ)
A hedge fund recently raised its stake in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC raised its holdings in Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after acquiring an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 25.10% of the company's stock.
一家对冲基金最近增持了Calliditas Treateutics AB(Publ)的股票。根据Ironwood Investment Management LLC提交给美国证券交易委员会的最新13F文件，该公司在第一季度将其在Calliditas Treateutics AB(Publ)(纳斯达克代码：CALT-GET评级)的持股增加了5.5%。该基金在本季度增持了1,495股后，持有该公司28,762股股票。截至最近提交给美国证券交易委员会的文件，Ironwood Investment Management LLC拥有Calliditas Treateutics AB(Publ)0.11%的股份，价值55.1万美元。机构投资者和对冲基金持有该公司25.10%的股票。
About Calliditas Therapeutics AB (publ)
关于Calliditas Treateutics AB(Publ)
(Get Rating)
(获取评级)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Calliditas Treateutics AB(Publ)是一家临床阶段的生物制药公司，专注于识别、开发和商业化用于孤儿适应症治疗的药物产品，最初的重点是肾脏和肝脏疾病。它提供Nefecon，一种口服布地奈德制剂，是一种治疗自身免疫性肾病免疫球蛋白A肾病的免疫抑制剂。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- Near-Term Headwinds Present An Opportunity In Ross Stores
- 免费获取StockNews.com关于Calliditas Treateutics AB(Publ)(CALT)的研究报告
- 2家电动汽车供应商在提出意见后上涨
- 应用材料公司业绩显示半导体市场放缓
- MarketBeat：回顾中的一周8/15-8/19
- 苹果股价可能再次上涨30%
- 近期逆风为Ross Stores带来机遇
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Calliditas Treateutics AB(Publ)Daily的新闻和评级-在下面输入您的电子邮件地址，以通过MarketBeat.com的免费每日电子邮件时事通讯接收对Calliditas Treateutics AB(Publ)和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧